Fig. 2

Rapamycin inhibits development of anti-graft immunity. a, b BM (10⁷ cells) from MII.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin (rapa), cyclosporine (CyA) where indicated or PBS was administered i.p. for 22 days commencing at BM transfer as indicated and mice were studied in parallel. Engraftment was determined within PBL at the time-points indicated (a) and in the spleen 5 or 6 weeks after BMT (b). Data are individual mice (a) with mean ± SEM (b) pooled from two separate experiments. c, d Recipient mice (C57BL/6, CD45.2⁺) were irradiated (1100 cGy) and a 1:1 mixture of nontransgenic (B6.SJL; CD45.1⁺) and MII.OVA (CD45.2⁺) or nontransgenic (B6.SJL; CD45.1⁺) and actin.OVA (CD45.2⁺) mice transferred i.v. Mice were administered rapamycin (0.6 mg/kg) or PBS i.p. for 22 days commencing at BM transfer (BMT). Six weeks after BMT, relative accumulation of donor leukocytes in the spleen (c) and donor HSPCs in BM were determined (d). Data are from a single experiment representative of two performed where the effect of rapamycin was similar but overall engraftment differed. Data show individual mice with mean ± SEM. ANOVA with Tukey’s post test. BM bone marrow